EFFICACY OF THE PAN PI3K-INHIBITOR COPANLISIB COMPARED TO SELECTIVE PI3K-A, -B, -Δ INHIBITORS IN MANTLE CELL LYMPHOMA (MCL)

被引：0
|
作者：
Zoellner, A. [1 ,2 ]
Arnd, J. [3 ]
Hutter, G. [2 ]
Zimmermann, Y. [2 ]
Hiddemann, W. [1 ,2 ]
Dreyling, M. [1 ,2 ]
机构：
[1] Univ Munich, Internal Med Haematol & Oncol 3, Munich, Germany
[2] Clin Cooperat Grp Leukemia, Munich, Germany
[3] Helmholtz Ctr Munich, Cooperat Grp Leukemia 2Clin, Munich, Germany
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1375
引用
收藏
页码：551 / 551
页数：1
相关论文
共 50 条
  • [1] Efficacy of PI3K-inhibitors in Mantle Cell Lymphoma (MCL)
    Zoellner, A. -K.
    Arndt, J.
    Hutter, G.
    Zimmermann, Y.
    Hiddemann, W.
    Dreyling, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 72 - 72
  • [2] Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
    Till, Kathleen J.
    Abdullah, Mariah
    Alnassfan, Tahera
    Janet, Gallardo Zapata
    Marks, Thomas
    Coma, Silvia
    Weaver, David T.
    Pachter, Jonathan A.
    Pettitt, Andrew R.
    Slupsky, Joseph R.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [3] Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
    Kathleen J. Till
    Mariah Abdullah
    Tahera Alnassfan
    Gallardo Zapata Janet
    Thomas Marks
    Silvia Coma
    David T. Weaver
    Jonathan A. Pachter
    Andrew R. Pettitt
    Joseph R. Slupsky
    Scientific Reports, 13
  • [4] Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma
    Kumar, Anshul
    Bhatia, Rohit
    Chawla, Pooja
    Anghore, Durgadas
    Saini, Vipin
    Rawal, Ravindra K.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2020, 20 (10) : 1158 - 1172
  • [5] Cotargeting of PIM, PI3K and Mtor in Mantle Cell Lymphoma (MCL)
    Freysoldt, Bianca
    Schnaiter, Andrea
    Fischer, Luca
    O'Neill, Michael
    Zimmermann, Yvonne
    Hutter, Grit
    Hiddemann, Wolfgang
    Dreyling, Martin H.
    BLOOD, 2015, 126 (23)
  • [6] PI3K a Selective Inhibitor Induces Growth Inhibition In Mantle Cell Lymphoma.
    Zhou, Yixin
    Jin, Linhua
    Pittaluga, Stefania
    Raffeld, Mark
    Miida, Takashi
    Tabe, Yoko
    BLOOD, 2010, 116 (21) : 757 - 757
  • [7] Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma
    Arribas, A.
    Napoli, S.
    Cascione, L.
    Gaudio, E.
    Bordone-Pittau, R.
    Barreca, M.
    Sartori, G.
    Chiara, T.
    Spriano, F.
    Rinaldi, A.
    Stathis, A.
    Stussi, G.
    Rossi, D.
    Emanuele, Z.
    Bertoni, F.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S40 - S40
  • [8] MODE OF ACTION OF DIFFERENT PI3K-INHIBITORS IN MANTLE CELL LYMPHOMA
    Hutter, G.
    Zimmermann, Y.
    Zoellner, A.
    Irrgang, P.
    Arnd, J.
    Hiddemann, W.
    Dreyling, M.
    HAEMATOLOGICA, 2016, 101 : 271 - 271
  • [9] COPANLISIB Inhibitor of Pan-Class I PI3K Isoforms Oncolytic
    Gras, J.
    DRUGS OF THE FUTURE, 2013, 38 (11) : 739 - 744
  • [10] PI3K-selective and PI3K/-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma
    Lampson, Benjamin L.
    Brown, Jennifer R.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (11) : 1267 - 1279
12345